Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery

Molecular Pharmaceutics

Volumn 13, Issue 2, 2016, Pages 609-620

  Page, Ken M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

clearance; Clint; dose prediction; human; in silico; in vitro; pharmacokinetics; prediction; protein binding; Vdss; volume of distribution; Vss

Indexed keywords

ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG DEVELOPMENT; DRUG MARKETING; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SYNTHESIS; BIOLOGICAL MODEL; COMPUTER SIMULATION; DOSE RESPONSE; METABOLIC CLEARANCE RATE; METABOLISM; VALIDATION STUDY;

DRUG;

COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

EID: 84957310691     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00840     Document Type: Article

References (44)

1. Prentis, R. A.; Lis, Y.; Walker, S. R. Pharmaceutical Innovation by the seven UK-owned pharmaceutical companies (1964-1985) Br. J. Clin. Pharmacol. 1987, 25, 387-396 10.1111/j.1365-2125.1988.tb03318.x
2. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3, 711-718 10.1038/nrd1470
3. Summerfield, S.; Jeffrey, P. Discovery DMPK: changing paradigms in the eighties, nineties and noughties Expert Opin. Drug Discovery 2009, 4, 207-218 10.1517/17460440902729405
4. Smith, D. A.; Jones, B. C.; Walker, D. Design of Drugs Involving the Concepts and Theories of Drug Metabolism and Pharmacokinetics Med. Res. Rev. 1996, 16 (3) 243-266 10.1002/(SICI)1098-1128(199605)16:3<243::AID-MED2>3.0.CO;2-Z
5. Eddershaw, P. J.; Beresford, A. P.; Bayliss, M. K. ADME/PK as part of a rational approach to drug discovery Drug Discovery Today 2000, 5 (9) 409-414 10.1016/S1359-6446(00)01540-3
6. Riley, R. J.; Martin, I. J.; Cooper, A. E. The influence of DMPK as an integrated partner in modern drug discovery Curr. Drug Metab. 2002, 3, 527-550 10.2174/1389200023337135
7. Beaumont, K.; Smith, D. A. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr. Op. Drug Disc. Dev. 2009, 12 (1) 61-71
8. McGinnity, D. F.; Collington, J.; Austin, R. P.; Riley, R. J. Evaluation of human pharmacokinetics, therapeutic dose and exposure predictions using marketed oral drugs Curr. Drug Metab. 2007, 8, 463-479 10.2174/138920007780866799
9. Houston, J. B. Utility Of In vitro Drug Metabolism Data In Predicting In vivo Metabolic Clearance Biochem. Pharmacol. 1994, 47, 1469-1479 10.1016/0006-2952(94)90520-7
10. Obach, R. S. Prediction of human clearance of twenty nine drugs from hepatic microsomal intrinsic clearance data: an investigation of in vitro half-life approach and non-specific binding to microsomes Drug Metab. Dispos. 1999, 27 (11) 1350-1359
11. Naritomi, Y.; Terashita, S.; Kimura, S.; Suzuki, A.; Kagayama, A.; Sugiyama, Y. Prediction Of Human Hepatic Clearance From In vivo Animal Experiments And In vitro Metabolic Studies With Liver Microsomes From Animals And Humans Drug Metab. Dispos. 2001, 29, 1316-1324
12. Ito, K.; Houston, J. B. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes Pharm. Res. 2004, 21, 785-792 10.1023/B:PHAM.0000026429.12114.7d
13. Riley, R. J.; McGinnity, D. F.; Austin, R. P. A Unified Model For Predicting Human Hepatic, Metabolic Clearance From In vitro Intrinsic Clearance Data In Hepatocytes and Microsomes Drug Metab. Dispos. 2005, 33, 1304-1311 10.1124/dmd.105.004259
14. Li, A. P.; Brent, J. A.; Pham, C.; Fackett, A.; Ruegg, C. E.; Silber, P. M. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential Chem.-Biol. Interact. 1999, 161, 17-35 10.1016/S0009-2797(99)00088-5
15. McGinnity, D. F.; Soars, M. G.; Urbanowicz, R. A. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance Drug Metab. Dispos. 2004, 32 (11) 1247-1253 10.1124/dmd.104.000026
16. Naritomi, Y.; Terashita, S.; Kagayama, A.; Sugiyama, Y. Utility Of Hepatocytes In Predicting Drug Metabolism: Comparison Of Hepatic Intrinsic Clearance In Rats and Humans In vivo And In vitro Drug Metab. Dispos. 2003, 31, 580-588 10.1124/dmd.31.5.580
17. Shibata, Y.; Takahashi, H.; Chiba, M.; Ishii, Y. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method Drug Metab. Dispos. 2002, 30, 892-896 10.1124/dmd.30.8.892
18. Soars, M. G.; McGinnity, D. F.; Grime, K.; Riley, R. J. The Pivotal Role of Hepatocytes in Drug Discovery Chem.-Biol. Interact. 2007, 168, 2-15 10.1016/j.cbi.2006.11.002
19. Sohlenius-Sternbeck, A.-K.; Afzelius, L.; Prussis, P.; Neelissen, J.; Hoogstraate, J.; Johansson, J.; Sternbeck, J.; Petersson, C. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds Xenobiotica 2010, 40 (9) 637-649 10.3109/00498254.2010.500407
20. Ito, K.; Houston, B. J. Prediction of Human Drug Clearance from in vitro and Preclinical Data Using Physiologically Based and Empirical Approaches Pharm. Res. 2005, 22, 103-110 10.1007/s11095-004-9015-1
21. Houston, J. B.; Galetin, A. Methods for predicting in vivo pharmacokinetics using data from in vitro assays Curr. Drug Metab. 2008, 9, 940-951 10.2174/138920008786485164
22. Hosea, N. A.; Collard, W. T.; Cole, S.; Maurer, T. S.; Fang, R. X.; Jones, H.; Kakar, S. M.; Nakai, Y.; Smith, B. J.; Webster, R.; Beaumont, K. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches J. Clin. Pharmacol. 2009, 49, 513-533 10.1177/0091270009333209
23. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25 10.1016/S0169-409X(96)00423-1
24. Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution Drug Discovery Today: Technol. 2004, 1, 337-341 10.1016/j.ddtec.2004.11.007
25. Obach, R. S.; Lombardo, F.; Waters, N. J. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds Drug Metab. Dispos. 2008, 36, 1385-1405 10.1124/dmd.108.020479
26. Rowland, M.; Tozer, T. N. In Clinical Pharmacokinetics Concepts and Applications, 3 rd ed.; Lea & Febiger: Philadelphia, PA, 1998; p 492.
27. Rowland, M.; Tozer, T. N. In Clinical Pharmacokinetics Concepts and Applications, 3 rd ed.; Lea & Febiger: Philadelphia, PA, 1998; p 84.
28. Rowland, M.; Tozer, T. N. In Clinical Pharmacokinetics Concepts and Applications, 3 rd ed.; Lea & Febiger: Philadelphia, PA, 1998; p 531.
29. Grime, K. H.; Barton, P.; McGinnity, D. Application of In Silico, In Vitro and Preclinical Pharmacokinetic Data for the Effective and Efficient Prediction of Human Pharmacokinetics Mol. Pharmaceutics 2013, 10, 1191-1206 10.1021/mp300476z
30. Khan, M. T. H. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches Curr. Drug Metab. 2010, 11, 285-295 10.2174/138920010791514306
31. Nissink, W.; Degorce, S.; Page, K. Lead Generation. Volume 67: Methods and Strategies (Methods and Principles in Medicinal Chemistry); Holenz, J., Ed.; in press.
32. Tang, H.; Hussain, A.; Leal, M.; Mayersohn, M.; Fluhler, E. Interspecies Prediction of Human Clearance Based on Scaling Data from One or Two Species Drug Metab. Dispos. 2007, 35 (10) 1886-1893 10.1124/dmd.107.016188
33. Leeson, P. D.; Springthorpe, B. The Influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6 (11) 881-890 10.1038/nrd2445
34. FDA guidance S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals, 2005.
35. Roden, D. M. Drug-Induced Prolongation of the QT Interval N. Engl. J. Med. 2004, 350, 1013-1022 10.1056/NEJMra032426
36. Bowlby, M. R.; Peri, R.; Zhang, H.; Dunlop, J. hERG (KCNH2 or Kv11.1)K+ channels: screening for cardiac arrhythmia risk Curr. Drug Metab. 2008, 9, 965-970 10.2174/138920008786485083
37. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834 10.1021/jm701122q
38. Braggio, S.; Montanari, D.; Rossi, T.; Ratti, E. Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates Expert Opin. Drug Discovery 2010, 5, 609-618 10.1517/17460441.2010.490553
39. Johnson, T. W.; Dress, K. R.; Edwards, M. Using the golden triangle to optimize clearance and oral absorption Bioorg. Med. Chem. Lett. 2009, 19, 5560-5564 10.1016/j.bmcl.2009.08.045
40. Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings Pharm. Sci. Technol. Today 1998, 1, 387-393 10.1016/S1461-5347(98)00097-2
41. Chang, G.; Steyn, S. J.; Umland, J. P.; Scott, D. O. Strategic Use of Plasma and Microsome Binding To Exploit in vitro Clearance in Early Drug Discovery ACS Med. Chem. Lett. 2010, 1, 50-53 10.1021/ml900012h
42. Austin, R. P.; Barton, P.; Cockcroft, S. L.; Wenlock, M. C.; Riley, R. J. The Influence of nonspecific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties Drug Metab. Dispos. 2002, 30, 1497-1503 10.1124/dmd.30.12.1497
43. Austin, R. P.; Barton, P.; Mohmed, S.; Riley, R. J. The binding of drugs to hepatocytes and its relationship to physicochemical properties Drug Metab. Dispos. 2005, 33, 419-425 10.1124/dmd.104.002436
44. Gertz, M.; Kilford, P. J.; Houston, J. B.; Galetin, A. Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations Drug Metab. Dispos. 2008, 36, 535-542 10.1124/dmd.107.018713